Search
Program Calendar
Browse By Day
Browse By Person
Browse By Room
Browse By Category
Browse By Session Type
Browse By Research Area
Search Tips
ASC Home
Personal Schedule
Sign In
X (Twitter)
Federal prosecutors have increasingly relied on Non-Prosecution Agreements (NPAs) to resolve charges of corporate wrongdoing. One primary rationale for the use of NPAs is that they reduce the collateral damages that may stem from criminal convictions. To date, there is limited research on the use and impact of such agreements, particularly when compared to other possible outcomes. This paper examines the impact of different sanction outcomes, including non-prosecution agreements, on the adverse publicity and stock performance of three similarly sized pharmaceutical companies charged with wrongdoing.